This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.
We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.
Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.
Patients who do not speak or understand English.
Any individual who is currently on an analgesic, antibiotic and/or mental health medication that is part of the panels.
Other
Other
Not listed
150 participants on analgesics, anti-infectives and psychotropics will be given pharmacogenomic recommendations for the risk of gene related adverse events prior to or during treatment.
We will be able to determine the barriers and facilitators of the implementation of the pharmacogenomic service in a health care facility. This will be done by using standardized questionnaires after each pharmacogenomic report is issued. The prescriber and the patient will both answer questions about the utility of the genetic results, the format of the report and the clarity of the content. Results will be recorded and summarized every 25 patients in order to improve the service and the recommendations through the study.
Click on the lead sponsor to view all of their trials.
University of British Columbia
Lead sponsor
Genome British Columbia
Collaborator
Genome Canada
Collaborator
Dynacare Laboratories, Inc.
Collaborator
